Adynxx Inc
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-… Read more
Adynxx Inc (ADYX) - Net Assets
Latest net assets as of September 2019: $-11.06 Million USD
Based on the latest financial reports, Adynxx Inc (ADYX) has net assets worth $-11.06 Million USD as of September 2019.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.25 Million) and total liabilities ($14.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.06 Million |
| % of Total Assets | -339.95% |
| Annual Growth Rate | 27.48% |
| 5-Year Change | -63.34% |
| 10-Year Change | 26.34% |
| Growth Volatility | 537.29 |
Adynxx Inc - Net Assets Trend (2000–2018)
This chart illustrates how Adynxx Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Adynxx Inc (2000–2018)
The table below shows the annual net assets of Adynxx Inc from 2000 to 2018.
| Year | Net Assets | Change |
|---|---|---|
| 2018-12-31 | $8.25 Million | -47.33% |
| 2017-12-31 | $15.67 Million | -51.18% |
| 2016-12-31 | $32.09 Million | -38.79% |
| 2015-12-31 | $52.42 Million | +132.88% |
| 2014-12-31 | $22.51 Million | +61.34% |
| 2013-12-31 | $13.95 Million | +14.83% |
| 2012-12-31 | $12.15 Million | -10.88% |
| 2011-12-31 | $13.63 Million | -45.07% |
| 2010-12-31 | $24.82 Million | +280.00% |
| 2009-12-31 | $6.53 Million | +125.96% |
| 2008-12-31 | $2.89 Million | +632.78% |
| 2007-12-31 | $-542.53K | +48.76% |
| 2006-12-31 | $-1.06 Million | +15.28% |
| 2005-12-31 | $-1.25 Million | -131.87% |
| 2004-12-31 | $-538.95K | -8.89% |
| 2003-12-31 | $-494.96K | -1956.21% |
| 2002-12-31 | $26.66K | -65.83% |
| 2001-12-31 | $78.04K | -25.25% |
| 2000-12-31 | $104.40K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adynxx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15783400900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2018)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.06% |
| Other Comprehensive Income | $-28.85K | -0.35% |
| Other Components | $166.70 Million | 2020.15% |
| Total Equity | $8.25 Million | 100.00% |
Adynxx Inc Competitors by Market Cap
The table below lists competitors of Adynxx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HIPPO VALLEY ESTATES LIMITED
XZIM:HIPO
|
$103.00 |
|
Peer To Peer Network
PINK:PTOP
|
$103.46 |
|
Bright Kindle Resources & Investments Inc
PSE:BKR
|
$103.55 |
|
First Abacus Financial Holdings Corp
PSE:FAF
|
$103.61 |
|
HAW Capital Corp
V:HAW-P
|
$102.34 |
|
Mushrooms Inc.
PINK:MSRM
|
$102.34 |
|
Winchester Equity Corporation
V:WEC
|
$101.94 |
|
BANK INTL INDON -A-
BE:BOZA
|
$101.90 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adynxx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2017 to 2018, total equity changed from 15,667,000 to 8,252,000, a change of -7,415,000 (-47.3%).
- Net loss of 8,417,000 reduced equity.
- Other comprehensive income decreased equity by 98.
- Other factors increased equity by 1,002,098.
Equity Change Factors (2017 to 2018)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.42 Million | -102.0% |
| Other Comprehensive Income | $-98.00 | -0.0% |
| Other Changes | $1.00 Million | +12.14% |
| Total Change | $- | -47.33% |
Book Value vs Market Value Analysis
This analysis compares Adynxx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $12.39 | $0.00 | x |
| 2000-12-31 | $6.65 | $0.00 | x |
| 2001-12-31 | $4.51 | $0.00 | x |
| 2002-12-31 | $1.33 | $0.00 | x |
| 2003-12-31 | $-23.56 | $0.00 | x |
| 2004-12-31 | $-21.90 | $0.00 | x |
| 2005-12-31 | $-47.33 | $0.00 | x |
| 2006-12-31 | $-38.90 | $0.00 | x |
| 2007-12-31 | $-19.22 | $0.00 | x |
| 2008-12-31 | $88.28 | $0.00 | x |
| 2009-12-31 | $222.70 | $0.00 | x |
| 2010-12-31 | $417.61 | $0.00 | x |
| 2011-12-31 | $172.78 | $0.00 | x |
| 2012-12-31 | $135.41 | $0.00 | x |
| 2013-12-31 | $117.24 | $0.00 | x |
| 2014-12-31 | $92.33 | $0.00 | x |
| 2015-12-31 | $136.39 | $0.00 | x |
| 2016-12-31 | $68.85 | $0.00 | x |
| 2017-12-31 | $21.90 | $0.00 | x |
| 2018-12-31 | $10.06 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adynxx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -102.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -379.83%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.17x
- Recent ROE (-102.00%) is above the historical average (-136.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -65.43% | 0.00% | 0.00x | 1.00x | $-139.55K |
| 2000 | -77.21% | 0.00% | 0.00x | 1.48x | $-91.05K |
| 2001 | -205.50% | 0.00% | 0.00x | 1.77x | $-168.17K |
| 2002 | -1408.11% | 0.00% | 0.00x | 1.09x | $-378.14K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.05 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.38 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.69 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.55 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.38 Million |
| 2008 | -126.88% | 0.00% | 0.00x | 1.10x | $-3.96 Million |
| 2009 | -11.69% | -52.72% | 0.22x | 1.03x | $-1.42 Million |
| 2010 | -12.48% | -234.83% | 0.05x | 1.02x | $-5.58 Million |
| 2011 | -101.61% | -756.08% | 0.13x | 1.03x | $-15.22 Million |
| 2012 | -40.37% | -399.24% | 0.09x | 1.13x | $-6.12 Million |
| 2013 | -157.51% | -1222.47% | 0.10x | 1.25x | $-23.37 Million |
| 2014 | -113.03% | -531.65% | 0.16x | 1.32x | $-27.70 Million |
| 2015 | -49.63% | -172.97% | 0.17x | 1.71x | $-31.26 Million |
| 2016 | -88.01% | -173.33% | 0.30x | 1.70x | $-31.45 Million |
| 2017 | -164.08% | -1273.25% | 0.06x | 2.10x | $-27.27 Million |
| 2018 | -102.00% | -379.83% | 0.23x | 1.17x | $-9.24 Million |
Industry Comparison
This section compares Adynxx Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adynxx Inc (ADYX) | $-11.06 Million | -65.43% | N/A | $102.99 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |